New Vaccine-Drug combo aims to fight tough lung cancer
NCT ID NCT07543172
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This study tests a combination of a cancer vaccine (CIMAVAX-EGF) and targeted drugs (sotorasib or adagrasib) in about 29 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The vaccine helps the immune system attack cancer cells, while the drugs block signals that make cancer grow. The goal is to see if this combo can keep the cancer from getting worse for longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.